PD-1 Inhibitor Raises PFS in Advanced Acral Melanoma

By News Health
1 hour Ago

(MedPage Today) — First-line treatment of advanced acral melanoma with the PD-1 inhibitor toripalimab (Loqtorzi) resulted in a small but statistically significant increase in progression-free survival (PFS) compared with treatment with dacarbazine…

Source link : https://www.medpagetoday.com/hematologyoncology/skincancer/119251

Author :

Publish date : 2026-01-02 19:17:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Gene-Editing Breakthrough Ends Transfusions for UK Patient

FFA Appears Earlier in Patients With Skin of Color

Swiss Hospital Director Describes the Rush to Treat Alpine Resort Bar Fire Injuries

Tardy Primary Vaccines Predict the Kids Most Likely to Miss Their MMR Shots

Gabapentin Under Scrutiny: 2025 Data Challenged Safety Profile

Federal Employees File Complaint Against Ban on Gender-Affirming Care